Integrin chatter and vascular function in diabetic retinopathy

Hormone and Metabolic Research

Volumn 29, Issue 12, 1997, Pages 643-645

  Preissner, K T ^a   Kanse, S M ^a   Hammes, H P ^b  

^a KERCKHOFF HEART CENTER   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Advanced Glycation Endproducts; Diabetic Retinopathy; Plasminogen Activation; Vascular Integrins; Vitronectin Receptors

Indexed keywords

INTEGRIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMAN; HYPOXIA; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RETINA NEOVASCULARIZATION;

EID: 0031453118     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979118     Document Type: Conference Paper

References (28)

1. Hynes, R. O.: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25 (1992)
2. Fässler, R., E. Georges-Labouesse, E. Hirsch: Genetic analysis of integrin function in mice. Curr Opin Cell Biol 8: 641-646 (1996)
3. Meredith, J. E., B. Fazeli, M. A. Schwartz: The extracellular matrix as a cell survival factor. Mol Biol Cell 4: 953-961 (1993)
4. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164 (1994)
5. Casaroli Marano, R. P., K. T. Preissner, S. Vilaro: Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 60: 5-17 (1995)
6. Preissner, K. T., B. Pötzsch: Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitro-nectin. Histol Histopathol 10: 239-251 (1995)
7. Hommes, H. P., A. Weiss, S. Hess, N. Araki, S. Horiuchi, M. Brownlee, K. T. Preissner: Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 75: 325-338 (1996)
8. Millauer, B., L. K. Shawver, K. H. Plate, W. Risau, A. Ullrich: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579 (1994)
9. Novogrodsky, A., A. Vanichkin, M. Patya, A. Gazit, N. Osherov, A. Levitzki: Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 264: 1319-1322 (1994)
10. Hammes, H. P., M. Brownlee, A. Joncyk, A. Sutter, K. T. Preissner: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 2: 529-533 (1996)
11. Strömblad, S., D. A. Cheresh: Cell adhesion and angiogenesis. Trends Cell Biol 6: 462-467 (1996)
12. Dano, K., P. A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L. S. Nielsen, L Skriver: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266 (1985)
13. Blasi, F., N. Behrendt, M. V. Cubellis, V. Ellis, L. R. Lund, M. T. Masucci, L. B. Moller, D. P. Olson, N. Pedersen, M. Ploug et al.: The urokinase receptor and regulation of cell surface plasminogen activator. Cell Differ Develop 32: 247-254 (1990)
14. Brunner, G., K. T. Preissner: Pericellular enzymatic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coagul Fibrinol 5: 625-639 (1994)
15. Preissner, K. T.: Structure and biological role of vitronectin. Ann Rev Cell Biol 7: 275-310 (1991)
16. Carmeliet, P., D. Collen: Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis.Trends Cardiovasc Med 5: 117-122 (1995)
17. Ossowski, L., G. Clunie, M.-T. Masucci, F. Blasi: In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115: 1107-1112 (1991)
18. Mandriora, S. J., G. Seghezzi, J. D. Vassalli, N. Ferrara, S. Wasi, R. Mazzieri, P. Mignatti, M. S. Pepper: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 270: 9709-9716 (1995)
19. Koolwijk, P., M. G. M. van Erck, W. J. A. de Vree, M. A. Vermeer, H. A. Weich, R. Hanemaaijer, V. W. M. van Hinsbergh: Cooperative effect of TNF α, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 132: 1177-1188 (1996)
20. Min, H. Y., L. V. Doyle, C. R. Vitt, C. L. Zandonella, J. R. Stratton-Thomas, M. A. Shuman, S. Rosenberg: Urokinase receptor antagonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428-2433 (1996)
21. Wie, Y., D. A. Waltz, N. Rao, R. J. Drummond, S. Rosenberg, H. A. Chapman: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32 380-32 388 (1994)
22. Gyetko, M. R., R. F. Todd III, C. C. Wilkinson, R. C. Sitrin: The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93: 1380-1387 (1994)
23. Kanse, S. M., C. Kost, O. G. Wilhelm, P. A. Andreasen, K. T. Preissner: The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 224: 344-353 (1996)
24. 3 binding to vitronectin. Nature 383: 441-443 (1996)
25. Kjoller, L., S. M. Kanse, T. Kirkegaard, K. W. Rodenburg, E. Ronne, S. L: Goodman, K. T. Preissner, L. Ossowski, P. A. Andreasen: Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232: 420-429 (1997)
26. 2-integrins, and scr-kinases within a single receptor complex of human monocytes. J Exp Med 181: 1381-1390 (1995)
27. Wie, Y., M. Lukashev, D. I. Simon, S. C. Bodary, S. Rosenberg, M. V. Doyle, H. A. Chapman: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555 (1996)
28. Resnati, M., M. Guttinger, S. Valcamonica, N. Sidenius, F. Blasi, F. Fazioli: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582 (1996)